Business Models & Investment Subcommittee


The Business Models & Investment Subcommittee strives to:

  • Map out the manufacturing process and considerations as they relate to optimizing the Business Model, including reimbursement and adoption into standard of care, for both autologous and allogeneic cell therapy products.

Projects and Objectives

  • The  Business Models & Investment Subcommittee will collect information from ISCT stakeholders via online surveys to assist in the development of educational webinars, white papers and roadmaps to support decision-making in cell therapy manufacturing.



Committee Chair


Bill Milligan
Steminent Biotherapeutics Inc.
Vancouver, BC, Canada 

Patrick Rivers, MBA

Aquilo Capital
San Francisco, CA, United States


Committee Members


Suzanne Farid, PhD
University College London
London, England
Asthika Goonewardene
SunTrust Robinson Humphrey 
New York, NY, United States
Stephen Hardt
San Francisco, CA, United States
Brian Hawkins, PhD
Seattle, WA, United States
David Hockins
Lake Zurich, IL, United States
Jeff Liter
B-MoGen Biotechnologies
Minneapolis, MN, United States
Jim Lovgren
Thermo Fisher Scientific
London, United Kingdom
Alex Lyness, PhD
West Pharmaceutical Services
Exton, PA, United States
Michael May, PhD
Toronto, ON, Canada
Jennifer Moody, PhD
Morphocell Technologies
Toronto, ON, Canada


Charles Mooney
Oklahoma Blood Institute
Oklahoma City, OK, United States

Deirdre-Ann Perry
Terumo BCT
Denver, CO, United States


Mark Sawicki, PhD
Irvine, CA, United States

Aletta Schnitzler, PhD
Bedford, MA, United States

Xiaokhui Zhang, PhD
Newark, NJ, United States
Allen Chen, PhD

© 2020 ISCT. All rights reserved. 
ISCT, and the ISCT logo are registered trademarks of the International Society for Cell and Gene Therapy.
The BEACON and lighthouse logo is a service mark of the International Society for Cell and Gene Therapy.

ISCT Privacy Policy